This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Theodore Van Putten, MD; Philip R. A. May, MD; Stephen R. Marder, MD; Lorraine A. Wittmann

Arch Gen Psychiatry. 1981;38(2):187-190.

Abstract
• Sixty-three newly admitted schizophrenic patients were given a test dose of thiothixene and their subjective response was recorded by a technician blind to clinical ratings. All patients were then treated with thiothixene in an active milieu setting. Patients varied widely in their subjective responses. An initial dysphoric response was a powerful predictor of both immediate and eventual drug refusal. Before treatment, dysphoric responders tended to be less symptomatic and did significantly better on the Continuous Performance Test. Dysphoric responders experienced significantly more extrapyramidal symptoms following the test dose. Some dysphoric responders did have a good outcome when treated with very low doses. We recommend that patients with a history of dysphoric response be given a very low dose initially.

Author Affiliations
From the Veterans Administration Medical Center, Brentwood, Los Angeles (Drs Van Putten, May, Marder, and Ms Wittmann), and the Department of Psychiatry, UCLA (Drs Van Putten, May, and Marder).

Footnotes
Accepted for publication Feb 11, 1980.

Reprint requests to Veterans Administration Medical Center, Wilshire and Sawtelle Boulevards, Brentwood, Los Angeles, CA 90073 (Dr Van Putten).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Depot and oral antipsychotics: patient preferences and attitudes are not the same thing
Patel et al.
J Psychopharmacol 2009;23:789-796.
ABSTRACT  

Patients' views and readmissions 1 year after involuntary hospitalisation
Priebe et al.
Br. J. Psychiatry 2009;194:49-54.
ABSTRACT | FULL TEXT  

Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride
Linden et al.
J Psychopharmacol 2006;20:815-823.
ABSTRACT  

Rationale and Parameters for Medication-Free Research in Psychosis
McGlashan
Schizophr Bull 2006;32:300-302.
FULL TEXT  

Subjective Experience and D2 Receptor Occupancy in Patients With Recent-Onset Schizophrenia Treated With Low-Dose Olanzapine or Haloperidol: A Randomized, Double-Blind Study
de Haan et al.
Am. J. Psychiatry 2003;160:303-309.
ABSTRACT | FULL TEXT  

Psychopharmacology: Insight and Comorbid SubstanceMisuse and Medication ComplianceAmong Patients With Schizophrenia
Kamali et al.
Psychiatr. Serv. 2001;52:161-166.
FULL TEXT  

Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia
Glick et al.
ANN INTERN MED 2001;134:47-60.
ABSTRACT | FULL TEXT  

Subjective Experience and Striatal Dopamine D2 Receptor Occupancy in Patients With Schizophrenia Stabilized by Olanzapine or Risperidone
de Haan et al.
Am. J. Psychiatry 2000;157:1019-1020.
ABSTRACT | FULL TEXT  

Non-Compliance With Treatment in Patients Suffering From Schizophrenia: a Study To Evaluate Possible Contributing Factors
Agarwal et al.
Int J Soc Psychiatry 1998;44:92-106.
ABSTRACT  

A Prospective, Multicenter Study of Patients' Refusal of Antipsychotic Medication
Hoge et al.
Arch Gen Psychiatry 1990;47:949-956.
ABSTRACT  

Toward a More Reliable Diagnosis of Akathisia
Van Putten and Marder
Arch Gen Psychiatry 1986;43:1015-1016.
ABSTRACT  

Costs and Benefits of Two Doses of Fluphenazine
Marder et al.
Arch Gen Psychiatry 1984;41:1025-1029.
ABSTRACT